Pharmacopsychiatry 2004; 37(1): 41-42
DOI: 10.1055/s-2004-815474
Letter
© Georg Thieme Verlag Stuttgart · New York

Effect of Risperidone on Prolactinoma

A Case ReportD. N. Mendhekar1 , R. C. Jiloha1 , P. K. Srivastava1
  • 1Department of Psychiatry, G.B. Pant Hospital, New Delhi
Further Information

Publication History

Received: 17.6.2002 Revised: 03.02.2003

Accepted: 26.2.2003

Publication Date:
29 January 2004 (online)

Risperidone induced galactorrhea and hyperprolactinemia have been reported but its role in the growth of prolactinoma is not yet conclusive, due to extreme rarity of such cases. We describe a woman, suffering from Bipolar Disorder-manic episode, who exhibited prolactinoma while on risperidone therapy. The withdrawl of risperidone resulted in disappearance of prolactinoma though her prolactin level remained elevated alongwith persistent galactorrhea. The change to olanzapine therapy did not show much change in serum prolactin level and galactorrhea. Ultimately, only adding of bromocriptine resulted in disappearance of symptoms of prolactinemia and normal serum prolactin level was achieved and galactorrhea stopped. Further study is recommended to find out relationship between the growth of prolactinoma and risperidone.

References

  • 1 Baptista T, Lacruz T, Angeles F, Silvera R, DE Medoza M T, Hernadez L. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration.  Pharmacopsychiatry. 2001;  34(6) 223-231
  • 2 Green A l, Brown W A. Prolactin and neuroleptic drugs.  Neurol Clin. 1988;  6 213-223
  • 3 Szymanski S, Lieberman J, Alvir J M, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J K, Woerner M, Cooper T. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.  Am J Psychiatry. 1995;  152 698-703
  • 4 Shiwach R S, Carmody T J. Prolactogenic effects of risperidone in male patients - a preliminary study.  Acta Psychiatr Scand. 1998;  98 81-83
  • 5 Robbins R J, Kern P A, Thomson II T L. Interaction between thioridazine and bromocriptine in a patient with a prolactin secreting pituitary adenoma.  Am J Medicine. 1984;  76 921-923
  • 6 Weingarten J C, Thompson T L. The effect of thioridazine on prolactinoma growth in a schizophrenic man; a case report.  Gen Hosp Psychiatry. 1985;  7 364-6
  • 7 Daradkeh T K, Aljouni K M. The effect of neuroleptics on prolactinoma growths in a Jordanian schizophrenic girl.  Acta Psychiatr Scand. 1988;  77 228-9
  • 8 Pal J K, Sarino W A. Effect of risperidone on prolactinoma growth in psychotic woman. Psychosom Med 2000 Sep-Oct 62(5): 736-8
  • 9 Tollin S R. Use of dopamine agonist bromocriptine and cabergoline in the management of risperidone induced hyperprolactinemia in-patient with psychotic disorder.  J Endocrinol Invest. 2000;  23(11) 765-770
  • 10 Canuso C M, Hanau M, Jhamb K K, Green A I. Olanzapine use in women with antipsychotic induced hyperprolactinemia.  Am J Psychiatry Oct. 1998;  155(10) 1458

Dr. DN Mendhekar

Department of Psychiatry

GB Pant Hospital

New Delhi - 110002

Email: dnmendhekar@vsnl.net